1998 Fiscal Year Final Research Report Summary
Establishment of New Immunotheapy using Dendritic Cells and Evaluation of Its Inhibitory Effect on Tumor Relapse.
Project/Area Number |
09671283
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | University of Tokyo |
Principal Investigator |
OSADA Takuya Univ. of Tokyo, Dept. Transfusion Medicine, Assistant., 医学部・附属病院, 助手 (90272559)
|
Co-Investigator(Kenkyū-buntansha) |
TAKAMIZAWA Masaru Univ of Tokyo, Dept. Pediatrics, Lecturer., 医学部・附属病院, 講師 (40216784)
NAGAWA Hirokazu Univ of Tokyo, 1st Dept. Surgery, Assist Prof., 医学部・附属病院, 助教授 (80228064)
MUTO Tetsuichirou Univ of Tokyo, 1st Dept. Surgery, Prof., 医学部・附属病院, 教授 (20110695)
TSUNO Nelson Univ of Tokyo, Dept. Transfusion Med, Assistant., 医学部・附属病院, 助手 (50282637)
SHIBATA Youichi Univ of Tokyo, Dept. Transfusion Med, Prof., 医学部・附属病院, 教授 (30010474)
|
Project Period (FY) |
1997 – 1998
|
Keywords | Immunotherapy / Dendritic Cell / Tumor Antigen / Gastrointestinal Cancer / Cytokine |
Research Abstract |
Dendritic cell (DC) is known to be a potent antigen presenting cell which can elicit primary immunoreaction. New immunotherapy using DCs are recently applied to malignant lymphoma and malignant melanoma, showing hopeful results. In this study, we tried to use this new immunological method to other malignancies, with special regard to gastrointestinal cancers. From our results, the optimal method of DC separation and tumor antigen purification was determined. Using murine tumor metastasis model, we evaluated the in vivo antitumor effect of this therapy. Comparing three groups, intraperitoneal injection of recombinant murine GM-CSF, pretreatment with GM-CSF gene transduced hepatocytes (intrasplenic injection), and control group, we found that the local supply of GM-CSF is important for eliciting strong antitumor immunity in the liver. We hope our findings would be helpful for the establishment of human antitumor immunotherapy that can inhibit tumor relapse after surgery.
|